Two Doses of HPV Vaccine Optimal, Third Dose Adds No Benefit


Women who receive two doses of HPV vaccine have higher prophylactic efficacy than women who receive only one dose, according to a database study.

Women who receive two doses of human papillomavirus (HPV) vaccine have higher prophylactic efficacy than women who receive only one dose, according to a database study. A third dose, however, appears to offer no further protective effect beyond the second dose.

Guidelines recommend vaccination for girls and boys aged 11 to 12, with catch-up doses available for those aged 13 to 26. Though research on HPV vaccination has proliferated over the last decade, some outstanding questions remain, said Burak Zeybek, MD, of the University of Texas Medical Branch in Galveston, at the Society of Gynecologic Oncology (SGO) Annual Meeting in National Harbor, Maryland. Among those questions include long-term impacts of vaccination, and the best approaches with regard to timing and dosing.

Zeybek presented results of a study that used insurance claims data from 11,335 women who received at least one dose of HPV vaccine. Of those, 1,975 received only dose, 2,089 received two doses, and 7,271 women received three or more doses.

Women who received only a single dose had higher incidence of high-grade cytology, cervical intraepithelial neoplasia (CIN)-II or CIN-III histology, and of adenocarcinoma in situ and invasive cancer. At year 5 after first dose, 2.3% of single-dose women had CIN-II or CIN-III histology, compared with 1.5% of those who received two doses, and 1.8% for three doses. Also at year 5, 4.3% of single-dose women were considered to be in a “high-risk group” (any of ASC-H, HSIL, CIN-II, CIN-III, adenocarcinoma in situ, or invasive cancer), compared with 3% of two-dose women and 3.9% of three-dose women.

The difference between one dose and two doses was significant for the high-risk grouping (P = .04), and there was a trend with regard to CIN-II or CIN-III histology (P = .09). Comparing two and three doses, however, did not reach significance for either the high-risk group (P = .17) or for CIN histology (P = .79).

“Longer follow-ups of the less than three dose cohorts in ongoing studies as well as appropriately designed and ethically justifiable randomized studies are needed to establish the protection offered by the alterative schedules at least beyond 10 years of vaccination,” Zeybek noted in his presentation. He noted that the study is limited by its use of claims data, which can contain coding errors, and it did not include those with public insurance or no insurance.

The study adds to growing evidence that two doses of HPV vaccine is sufficient. In 2016, the Centers for Disease Control and Prevention changed its recommendation from three to two doses, arguing that it will lead to better coverage without loss of efficacy.

Related Videos
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Related Content